相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Insulin Fact Sheet in Type 1 and 2 Diabetes Mellitus and Trends of Antidiabetic Medication Use in Insulin Users with Type 2 Diabetes Mellitus: 2002 to 2019
Jiyun Park et al.
Diabetes & Metabolism Journal (2023)
Introduction: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Diabetes Fact Sheet in Korea 2021
Jae Hyun Bae et al.
DIABETES & METABOLISM JOURNAL (2022)
No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects
Yu Kyong Kim et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
Jaehyun Bae et al.
DIABETES & METABOLISM JOURNAL (2021)
Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State
Kyungho Jang et al.
CLINICAL THERAPEUTICS (2020)
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Marc Foretz et al.
NATURE REVIEWS ENDOCRINOLOGY (2019)
Empagliflozin: A Review in Type 2 Diabetes
James E. Frampton
DRUGS (2018)
Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
Eugene Han et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers
Sreeraj Macha et al.
CLINICAL THERAPEUTICS (2015)
Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats
Jong-Hwa Lee et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers
Sreeraj Macha et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects
Donghoon Shin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Clinical Pharmacokinetics of Metformin
Garry G. Graham et al.
CLINICAL PHARMACOKINETICS (2011)
Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-γ Agonist: A Single- and Multiple-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects
Jung Won Kim et al.
CLINICAL THERAPEUTICS (2011)
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
S. Kasichayanula et al.
DIABETES OBESITY & METABOLISM (2011)
Metformin: An update
D Kirpichnikov et al.
ANNALS OF INTERNAL MEDICINE (2002)
分享论文
